Management of Mixed-Phenotype Acute Leukemia in the East of France

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Recruiting	`NCT04872790` - Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	Phase 1
Recruiting	`NCT04067336` - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Recruiting	`NCT03959085` - Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	Phase 3
Completed	`NCT02135874` - Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia	Phase 2
Suspended	`NCT03128034` - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	Phase 1/Phase 2
Recruiting	`NCT04065399` - A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation	Phase 1/Phase 2
Completed	`NCT02921061` - Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	Phase 1/Phase 2
Recruiting	`NCT05476770` - Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	Phase 1
Recruiting	`NCT04128501` - Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	Phase 2
Recruiting	`NCT06013423` - Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases	Phase 2
Recruiting	`NCT03957915` - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia	Early Phase 1
Not yet recruiting	`NCT06289673` - Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma	Phase 4
Completed	`NCT05433532` - Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients	Phase 2
Recruiting	`NCT03843528` - Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation	Phase 1
Active, not recruiting	`NCT05326516` - A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia	Phase 1
Recruiting	`NCT05457556` - Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome	Phase 3
Completed	`NCT00723099` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Phase 2
Recruiting	`NCT05316701` - Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	Phase 3
Terminated	`NCT01887587` - Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia	Phase 1

NCT number	NCT03599869
Study type	Observational
Source	Central Hospital, Nancy, France
Contact
Status	Not yet recruiting
Phase
Start date	September 2018
Completion date	June 2019

Management of Mixed-Phenotype Acute Leukemia in the East of France — ELABEST

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms